Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Multimodal Assessment of Neuromuscular Electrical Stimulation (NMES) Effects on Respiratory and Peripheral Muscles in Chronic Obstructive Pulmonary Disease (COPD) (NMES in COPD)

11 novembre 2026 mis à jour par: Universitas Padjadjaran

Comparative Effects of Targeted Neuromuscular Electrical Stimulation (NMES) on Respiratory and Peripheral Muscles in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Multimodal Assesment Using Diaphragm Ultrasound and Plasma Biomarkers (Interleukin-6 and Insulin-like Growth Factor- 1)

The goal of this clinical trial is to learn if targeted neuromuscular electrical stimulation (NMES) can treat respiratory and peripheral muscle weakness in patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are:

  • Does targeted NMES improve diaphragm thickening fraction and excursion as measured by diaphragm ultrasound?
  • What are the comparative effects of targeted NMES on plasma biomarkers, specifically Interleukin-6 (IL-6) and Insulin-like Growth Factor-1 (IGF-1)? Researchers will compare three groups: the first intervention group receiving intercostal NMES combined with Pursed-Lip Breathing (PLB), the second intervention group receiving quadriceps NMES combined with PLB, and a control group receiving sham upper trapezius NMES combined with PLB, to see if targeted NMES provides superior improvements in respiratory and peripheral muscle function.

Participants will:

  • Undergo baseline screening, including a diaphragm ultrasound and a blood draw for plasma biomarkers (IL-6 and IGF-1)
  • Be randomly assigned to one of the three groups to receive either intercostal NMES, quadriceps NMES, or sham upper trapezius NMES, all combined with Pursed-Lip Breathing exercises
  • Complete a post-intervention assessment involving repeat ultrasound imaging and biomarker analysis to evaluate muscle and systemic changes

Aperçu de l'étude

Description détaillée

Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic airflow limitation and progressive respiratory and peripheral muscle dysfunction. While pulmonary rehabilitation is a cornerstone of management, severe breathlessness often limits a patient's exercise tolerance. Neuromuscular Electrical Stimulation (NMES) offers an alternative modality to train specific muscle groups without inducing severe dyspnea. However, the comparative efficacy of stimulating respiratory muscles versus peripheral muscle groups requires deeper investigation using precise physiological and biochemical markers.

This study utilizes a three-arm randomized controlled design to evaluate and compare the localized and systemic effects of targeted NMES. The mechanical properties of the respiratory system will be monitored using diaphragm ultrasound, focusing on active contractility and movement. Concurrently, systemic inflammation and muscle anabolic responses will be analyzed through plasma biomarkers to understand the underlying biomolecular pathways.

Upon meeting the eligibility criteria and providing written informed consent, the 45 participants will be randomly assigned to one of three study arms in a 1:1:1 ratio. All participants will undergo a standardized baseline assessment. Following the allocation, each group will complete their designated 8-week intervention protocol consisting of 3 sessions per week (total of 24 sessions) concurrently with Pursed-Lip Breathing (PLB) training. A comprehensive post-intervention reassessment will be conducted immediately following the final session to determine the comparative physiological and biochemical outcomes.

Type d'étude

Interventionnel

Inscription (Estimé)

45

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • West Java
      • Bandung, West Java, Indonésie
        • Recrutement
        • Faculty of Medicine Universitas Padjadjaran

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

40 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patients diagnosed with stable Chronic Obstructive Pulmonary Disease (COPD), GOLD spirometric grade 2-4 (post-bronchodilator FEV1/FVC <0.70 with FEV1 <80% predicted), confirmed by a pulmonologist.
  • Age ≥ 40 years old.
  • Willing to participate in the study and sign the written informed consent form.

Exclusion Criteria:

  • Recent thoracic or abdominal surgery, pneumothorax, or a history of spontaneous pneumothorax.
  • Participation in other structured respiratory muscle training or pulmonary rehabilitation programs that may confound the study results.
  • Presence of neuromuscular, bulbar, laryngeal, or other disorders that may independently impair respiratory muscle function.
  • Use of a cardiac pacemaker or any metal/electronic implant at the intended stimulation area.
  • Diagnosis of heart failure classified as NYHA (New York Heart Association) class III-IV.
  • Presence of skin lesions, open wounds, or active dermatitis in the intended electrode placement areas.
  • Current use of systemic (oral) corticosteroids or history of use within 4 weeks prior to enrollment.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Intercostal NMES + PLB

Participants receive targeted NMES to the intercostal muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Intercostal Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the intercostal muscles

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Expérimental: Quadriceps NMES + PLB

Participants receive targeted NMES to the quadriceps muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Quadriceps Neuromuscular Electrical Stimulation (NMES) is a procedure that uses small electrical impulses delivered through electrodes on the skin to stimulate motor nerves and cause passive muscle contractions which will be applied to the quadriceps muscles

Comparateur placebo: Sham NMES + PLB

Participants receive sham NMES to the upper trapezius muscles combined with Pursed-Lip Breathing (PLB) exercises. The protocol is administered 3 times per week for 8 weeks.

Pursed-lip breathing is a simple respiratory exercise that involves inhaling slowly through your nose and exhaling gently through tightly puckered or "pursed" lips (as if whistling or blowing out a candle).

Sham Neuromuscular Electrical Stimulation (NMES) is a control procedure that delivers minimal electrical impulses via transcutaneous skin patches to the upper trapezius muscles, generating only a mild tingling sensation as a placebo effect without triggering any passive muscle contractions.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Diaphragm Excursion (DE)
Délai: Baseline (Week 0) and post-intervention (Week 8)

Measured via B-mode or M-mode transabdominal ultrasound during quiet and deep breathing to evaluate the distance the diaphragm travels vertically. A higher excursion value indicates better diaphragmatic mobility.

Baseline (Week 0) and post-intervention (Week 8)
Diaphragm Thickening Fraction (TF)
Délai: Baseline (Week 0) and post-intervention (Week 8)

Calculated using the formula: [(Thickness at end-inspiration - Thickness at end-expiration) / Thickness at end-expiration] x 100%. Measured via high-frequency linear ultrasound at the zone of apposition to assess diaphragmatic contractile function.

Baseline (Week 0) and post-intervention (Week 8)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Plasma Interleukin-6 (IL-6) Levels
Délai: Baseline (Week 0) and post-intervention (Week 8)

Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate systemic inflammatory profiles. Decreased levels indicate a reduction in systemic inflammation.

Baseline (Week 0) and post-intervention (Week 8)
Change in Plasma Insulin-like Growth Factor-1 (IGF-1) Levels
Délai: Baseline (Week 0) and post-intervention (Week 8)

Measured via Enzyme-Linked Immunosorbent Assay (ELISA) from venous blood samples to evaluate muscle anabolic activity and systemic growth factor response. Increased levels indicate an improved anabolic state.

Baseline (Week 0) and post-intervention (Week 8)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Six-Minute Walk Test (6MWT) Distance
Délai: Baseline (Week 0) and post-intervention (Week 8)

Measured by the total distance in meters that a participant can walk quickly on a flat, hard surface in a period of 6 minutes. It evaluates functional exercise capacity.

Baseline (Week 0) and post-intervention (Week 8)
Modified Medical Research Council (mMRC) Dyspnea Scale
Délai: Baseline (Week 0) and post-intervention (Week 8)

A questionnaire used to rate the baseline dyspnea (breathlessness) on a scale from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house). Lower scores indicate less respiratory disability.

Baseline (Week 0) and post-intervention (Week 8)
COPD Assessment Test (CAT) Score
Délai: Baseline (Week 0) and post-intervention (Week 8)

An 8-item questionnaire measuring the health status impairment in COPD patients. Scores range from 0 to 40, where higher scores signify a worse health status and severe impact of COPD on the patient's life.

Baseline (Week 0) and post-intervention (Week 8)
Modified Borg Scale (MBS) for Dyspnea
Délai: Baseline (Week 0) and post-intervention (Week 8)

A categorical scale ranging from 0 (no breathlessness at all) to 10 (maximal breathlessness) used to assess the patient's perceived level of shortness of breath during functional activity or rest.

Baseline (Week 0) and post-intervention (Week 8)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 octobre 2027

Achèvement de l'étude (Estimé)

1 mars 2028

Dates d'inscription aux études

Première soumission

26 octobre 2026

Première soumission répondant aux critères de contrôle qualité

26 octobre 2026

Première publication (Réel)

2 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be made publicly available to protect participant privacy

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner